Take a look at our previous reports:
H1 Report
2024
View Report
Annual Report
2023
View Report
H1 Report
2023
View Report
Annual Report
2022
View Report
Annual Report 2024
Twitter
LinkedIn
en
English
Dutch
Hauptmenü
change report
English
Dutch
Home
At a Glance
Letter to Our Stakeholders
Key Company Facts
2024 Achievements and Post-Period Events
2024 Financial Highlights
The Galapagos Shares in 2024
Our Vision and Mission
Strategy to Unlock Value
About this Report
Platforms and Portfolio
Cell Therapies and Small Molecules
R&D Pipeline in Oncology and Immunology
Oncology
GLPG5101: CD19 CAR-T in R/R NHL
GLPG5201: CD19 CAR-T in R/R CLL and RT
GLPG5301: BCMA CAR-T in R/R MM
Uza-cel
Next-generation Programs
Immunology
Jyseleca® Franchise
TYK2 Program: GLPG3667
Sustainability Statements
General Disclosures
Basis for Preparation
Our Sustainability Commitment - Forward, Sustainably
Our Sustainability Governance
Double Materiality Assessment
Our Ambition
Environmental Information
Climate Change
EU Taxonomy Statement
EU Taxonomy Tables
Social Information
Own Workforce
Patients, Consumers and End-Users
Governance Information
Business Conduct
Entity Specific Information
Annexes
Advancing the United Nations (UN) Sustainable Development Goals (SDGs)
Reference Table
EU Legislation Datapoints
Corporate Governance
Corporate Governance Policies
Board of Directors
Committees
Executive Committee
Share Capital and Shares
Shareholders
Remuneration Policy
Remuneration Report
Introduction
Board of Directors
Executive Committee
Equity Components of the Remuneration
Evolution of Remuneration
Pay-Ratio
Minimum Share Ownership
Contractual Provisions Regarding Compensation for Severance for Executive Committee Members
Severance Payments
Claw-Back and Malus
Deviations from the Remuneration Policy
Conflict of Interests and Related Parties
Code of Conduct
Statement by the Board of Directors
Risk Management
Risk Management and Internal Control
Detailed Description of the Risk Factors in Form 20-F
Risks Related to Product Development and Regulatory Approval
Risks related to Commercialization of Future Products
Risks Related to Our Financial Position and Need for Additional Capital
Risks Related to Our Reliance on Third Parties
Risks Related to Our Intellectual Property
Risks Related to Our Competitive Position
Risks Related to Our Organization, Structure and Operation
Market Risks Relating to the Galapagos Shares
General Statement about Galapagos’ Risks
Financial Statements
Consolidated Financial Statements
Statements of Income and Comprehensive Income/Loss (-)
Statements of Financial Position
Cash Flow Statements
Statements of Changes in Equity
Notes to the Consolidated Financial Statements
Notes 1-10
1.
General Information
2.
Summary of Significant Transactions
3.
Material Accounting Policies
4.
Critical Accounting Judgments and Key Sources of Estimation Uncertainty
5.
Discontinued Operations and Assets Held for Sale
6.
Segment Information
7.
Total Net Revenues from Our Continuing Operations
8.
Operating costs and Other Operating Income
9.
Staff Costs
10.
Fair Value Adjustments, Net Currency Exchange Differences and Other Financial Income/Expenses
Notes 11-20
11.
Income Taxes
12.
Earnings per Share
13.
Goodwill and Impairment of Goodwill
14.
Intangible Assets Other than Goodwill
15.
Property, Plant and Equipment
16.
Equity Investments
17.
Other Non-Current Assets
18.
Research and Development Incentives Receivables
19.
Inventories
20.
Trade and Other Receivables and Other Current Assets
Notes 21-30
21.
Non-Current and Current Financial Investments
22.
Cash and Cash Equivalents
23.
Share Capital and Other Reserves
24.
Deferred Tax
25.
Lease Liabilities
26.
Trade and Other Liabilities and Other Non-Current Liabilities
27.
Deferred Income
28.
Details of the NovAlix Transaction
29.
Note to the Cash Flow Statement
30.
Off-Balance Sheet Arrangements
Notes 31-36
31.
Share-Based Payments
32.
Related Parties
33.
Consolidated Companies as of December 31, 2024
34.
Financial Risk Management
35.
Statutory Auditor’s Remuneration
36.
Events after Balance Sheet Date
Overview Statutory Results
Auditor's Report
Report of the Statutory Auditor
Report of the Statutory Auditor
(Sustainability Statements)
At a Glance
Letter to Our Stakeholders
Key Company Facts
2024 Achievements and Post-Period Events
2024 Financial Highlights
The Galapagos Shares in 2024
Our Vision and Mission
Strategy to Unlock Value
About this Report
Platforms and Portfolio
Cell Therapies and Small Molecules
R&D Pipeline in Oncology and Immunology
Oncology
GLPG5101: CD19 CAR-T in R/R NHL
GLPG5201: CD19 CAR-T in R/R CLL and RT
GLPG5301: BCMA CAR-T in R/R MM
Uza-cel
Next-generation Programs
Immunology
Jyseleca® Franchise
TYK2 Program: GLPG3667
Sustainability Statements
General Disclosures
Basis for Preparation
Our Sustainability Commitment - Forward, Sustainably
Our Sustainability Governance
Double Materiality Assessment
Our Ambition
Environmental Information
Climate Change
EU Taxonomy Statement
EU Taxonomy Tables
Social Information
Own Workforce
Patients, Consumers and End-Users
Governance Information
Business Conduct
Entity Specific Information
Annexes
Advancing the United Nations (UN) Sustainable Development Goals (SDGs)
Reference Table
EU Legislation Datapoints
Corporate Governance
Corporate Governance Policies
Board of Directors
Committees
Executive Committee
Share Capital and Shares
Shareholders
Remuneration Policy
Remuneration Report
Introduction
Board of Directors
Executive Committee
Equity Components of the Remuneration
Evolution of Remuneration
Pay-Ratio
Minimum Share Ownership
Contractual Provisions Regarding Compensation for Severance for Executive Committee Members
Severance Payments
Claw-Back and Malus
Deviations from the Remuneration Policy
Conflict of Interests and Related Parties
Code of Conduct
Statement by the Board of Directors
Risk Management
Risk Management and Internal Control
Detailed Description of the Risk Factors in Form 20-F
Risks Related to Product Development and Regulatory Approval
Risks related to Commercialization of Future Products
Risks Related to Our Financial Position and Need for Additional Capital
Risks Related to Our Reliance on Third Parties
Risks Related to Our Intellectual Property
Risks Related to Our Competitive Position
Risks Related to Our Organization, Structure and Operation
Market Risks Relating to the Galapagos Shares
General Statement about Galapagos’ Risks
Financial Statements
Consolidated Financial Statements
Statements of Income and Comprehensive Income/Loss (-)
Statements of Financial Position
Cash Flow Statements
Statements of Changes in Equity
Notes to the Consolidated Financial Statements
Notes 1-10
1.
General Information
2.
Summary of Significant Transactions
3.
Material Accounting Policies
4.
Critical Accounting Judgments and Key Sources of Estimation Uncertainty
5.
Discontinued Operations and Assets Held for Sale
6.
Segment Information
7.
Total Net Revenues from Our Continuing Operations
8.
Operating costs and Other Operating Income
9.
Staff Costs
10.
Fair Value Adjustments, Net Currency Exchange Differences and Other Financial Income/Expenses
Notes 11-20
11.
Income Taxes
12.
Earnings per Share
13.
Goodwill and Impairment of Goodwill
14.
Intangible Assets Other than Goodwill
15.
Property, Plant and Equipment
16.
Equity Investments
17.
Other Non-Current Assets
18.
Research and Development Incentives Receivables
19.
Inventories
20.
Trade and Other Receivables and Other Current Assets
Notes 21-30
21.
Non-Current and Current Financial Investments
22.
Cash and Cash Equivalents
23.
Share Capital and Other Reserves
24.
Deferred Tax
25.
Lease Liabilities
26.
Trade and Other Liabilities and Other Non-Current Liabilities
27.
Deferred Income
28.
Details of the NovAlix Transaction
29.
Note to the Cash Flow Statement
30.
Off-Balance Sheet Arrangements
Notes 31-36
31.
Share-Based Payments
32.
Related Parties
33.
Consolidated Companies as of December 31, 2024
34.
Financial Risk Management
35.
Statutory Auditor’s Remuneration
36.
Events after Balance Sheet Date
Overview Statutory Results
Auditor's Report
Report of the Statutory Auditor
Report of the Statutory Auditor
(Sustainability Statements)
Downloads
Search
Home
Privacy Policy
Privacy Policy
Downloads
Financial Calendar
Glossary of Terms
